H1 Antihistaminics
Phase 3Small molecule
H1 Antihistaminics is one of 6 small molecule programs targeting Premedication. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Premedication
#DrugCompanyPhaseTrials
1Duragesic
CCephalon
Approved
Ketalar
AAultman Health Foundation
Approved
H1 Antihistaminics
EErasmus Medical Center
Phase 3
Robinul
Jazz PharmaceuticalsPreclinical
Brufen
Boehringer IngelheimPreclinical
No Premedication
YYonsei University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for H1 Antihistaminics. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- EErasmus Medical Center